Related Experiment Video

Updated: May 12, 2026

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
05:45

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System

Published on: January 9, 2020

Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway

Zhizhong Li1, Yunyu Zhang, Krishnan Ramanujan

  • 1Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA. zhizhong.li@novartis.com

Cancer Research
|March 29, 2013
PubMed

Insights

High mobility group AT-hook 2 (HMGA2) drives embryonic rhabdomyosarcoma (ERMS) by upregulating IGF2BP2, which stabilizes NRAS. This HMGA2-IGF2BP2-NRAS pathway is crucial for ERMS tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Embryonic rhabdomyosarcoma (ERMS) is the most common pediatric soft-tissue tumor.
  • Understanding the molecular drivers of ERMS is critical for developing targeted therapies.

Purpose of the Study:

  • To identify key molecular factors driving ERMS development.
  • To elucidate the signaling pathways involved in ERMS pathogenesis.

Main Methods:

  • Analysis of high mobility group AT-hook 2 (HMGA2) expression in ERMS cells and normal myoblasts.
  • Investigated the role of HMGA2 in cell proliferation, survival, and tumor outgrowth.
  • Examined the interaction between HMGA2, IGF2BP2, and NRAS.
  • Utilized shRNA-mediated NRAS attenuation and MEK/ERK pathway inhibition.

Main Results:

  • HMGA2 is highly expressed in ERMS and essential for tumor progression.
  • HMGA2 upregulates insulin-like growth factor (IGF) mRNA-binding protein 2 (IGF2BP2).
  • IGF2BP2 stabilizes NRAS mRNA and protein, a frequent mutation in ERMS.
  • The HMGA2-IGF2BP2-NRAS axis is required for ERMS maintenance.

Conclusions:

  • The HMGA2-IGF2BP2-NRAS signaling pathway is a critical oncogenic driver in ERMS.
  • Targeting this pathway may offer novel therapeutic strategies for ERMS.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...